GlassScriptPhysician profile
Ashley Duncan
NPI 1649888413
$1,193.38
in general payments reported to CMS, 2019-2025
24 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.49 · 2022: $95.27 · 2023: $253 · 2024: $321 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173.81 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $169.39 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $149.29 | 2024-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $123.80 | 2022-2025 | |
| Lilly USA, LLC | $65.61 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $64.15 | 2024-2025 | Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $47.91 | 2023-2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.65 | 2025 | Caplyta |
| Exact Sciences Corporation | $43.21 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $41.12 | 2023 | |
| Phathom Pharmaceuticals, INC. | $34.85 | 2024-2025 | Voquezna |
| Cardiva Medical, INC. | $25.64 | 2023 | Cardiva Vascade 6/7f Vcs |
| Mannkind Corporation | $24.81 | 2025 | |
| Paratek Pharmaceuticals, INC. | $23.60 | 2024 | Nuzyra |
| Cvrx, INC. | $20.96 | 2025 | Barostim Neo System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.79 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $18.21 | 2024 | Qelbree |
| Medtronic, INC. | $18.20 | 2025 | Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $17.85 | 2021 | |
| Abbott Laboratories | $16.99 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2024 | Jardiance |
| Sanofi Pasteur INC. | $14.97 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.70 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $4.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.